Publication:
Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis

Simple item page
dc.contributor.authorAKYÜZ, GÜLSEREN DERYA
dc.contributor.authorsOzsoy-Unubol, Tugba; Akyuz, Gulseren; Mirzayeva, Samaya; Guler, Tuba
dc.date.accessioned2022-04-25T00:11:47Z
dc.date.available2022-04-25T00:11:47Z
dc.date.issued2020
dc.description.abstractObjectives: This study aims to evaluate pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis (OP). Patients and methods: Between May 2016 and January 2018, a total of 138 patients (mean age 63.78 years; range, 50 to 70 years) with postmenopausal OP were retrospectively analyzed. All patients were previously treated with denosumab (DEN) and parenteral forms of bisphosphonates such as zoledronic acid (ZOL) and ibandronate (IBN). The pain severity was evaluated using the Visual Analog Scale (VAS) and Brief Pain Inventory-Short Form (BPI-SF). The quality of life was evaluated using the Quality of Life Questionnaire of the European Foundation for Osteoporosis (Qualeffo-41). For the evaluation of patient satisfaction, a three-item questionnaire including satisfaction with the medication, route, and frequency of administration was applied. Results: Of the patients, 50 received DEN, 48 received ZOL, and 40 received IBN treatment. There was no significant difference in any of the pain parameters. All domains of the Qualeffo-41 were similar among the three groups. The patients in the DEN group were more satisfied with their medication (DEN: 88%, ZOL: 43.75%, and IBN: 52.5%), its administration route (DEN: 84%, ZOL: 43.8%, and IBN: 57.5%), and the frequency of its administration (DEN: 84%, ZOL: 56.25%, and IBN: 52.5%) (p=0.0001). Conclusion: Neither of the medication showed a superior effect on quality of life. However, patients were more satisfied with medications used in a six-month interval and applied subcutaneously. Of these three treatment options, DEN seems to be a step ahead in terms of patient satisfaction.
dc.identifier.doi10.5606/tftrd.2020.4114
dc.identifier.issn2587-0823
dc.identifier.pubmed33089082
dc.identifier.urihttps://hdl.handle.net/11424/263967
dc.identifier.wosWOS:000569098300004
dc.languageeng
dc.publisherBAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK
dc.relation.ispartofTURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOsteoporosis
dc.subjectpain
dc.subjectpatient satisfaction
dc.subjectquality of life
dc.subjecttreatment
dc.subjectVERTEBRAL FRACTURES
dc.subjectZOLEDRONIC ACID
dc.subjectEUROPEAN FOUNDATION
dc.subjectWOMEN
dc.subjectALENDRONATE
dc.subjectEFFICACY
dc.subjectQUESTIONNAIRE
dc.subjectPREFERENCES
dc.subjectRELIABILITY
dc.subjectIBANDRONATE
dc.titleEvaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis
dc.typearticle
dspace.entity.typePublication
local.avesis.id1944d21b-d7e7-47ad-b01d-0cd9a9f06b06
local.import.packageSS39
local.indexed.atWOS
local.journal.numberofpages9
local.journal.quartileQ4
oaire.citation.endPage270
oaire.citation.issue3
oaire.citation.startPage262
oaire.citation.titleTURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
oaire.citation.volume66
relation.isAuthorOfPublicationa0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9
relation.isAuthorOfPublication.latestForDiscoverya0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9

Files

Collections

Research Outputs